OR WAIT null SECS
Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. The project completion was announced in an Oct. 12, 2020 press release.
Through the expansion, the company has doubled the size of the facility, which is now 15,000 ft.2. The existing facility laboratory space has been refurbished and an additional 3500 ft.2 of laboratory space has been added, enhancing the facility’s capacity and enabling the provision of larger process crystallization development or up to 20-L scale.
“We have seen an increase in demand for services, and specifically for larger-scale crystallization projects, so this expansion increases our efficiency and ability to respond to these requests,” said Tom Loewald, CEO of Cambrex, in the press release. “The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases our flexibility to work on projects at all stages of drug development.”
The company’s Edinburgh site provides solid form development services for drug substance and drug product, including solid state investigations, crystallization process development, and good manufacturing practice analytical services. Site scientists work on standalone projects as well as integrated process development services.